Publications by Elisa Oricchio

Related publications (29)

Development of patient-derived lymphomoids with preserved tumor architecture for lymphoma therapy screening

Albert Santamaria Martinez, Elisa Oricchio, Justine Epiney, Divyanshu Srivastava, Daniele Tavernari

The efficacy of anti-cancer therapies depends on the genomic composition of the tumor, its microenvironment, spatial organization, and intra-tumor heterogeneity. B-cell lymphomas are a heterogeneous group of tumors emerging from B-cells at different stages ...

Nature Portfolio2024

Histone Modifications in Development and Malignancy

Elisa Oricchio

Non-Hodgkin lymphoma (NHL) development is driven by the accumulations of multiple genetic, epigenetic, and chromosomal alterations. These lesions can lead to modifications of the chromatin architecture. To identify novel oncogenic interactions driven by mo ...

AMER SOC HEMATOLOGY2019

Histone acetylation dynamics modulates chromatin conformation and allele-specific interactions at oncogenic loci

Elisa Oricchio, Natalya Katanayeva, Stephanie Jocelyne Sungalee, Ruxandra-Andreea Lambuta, Daniele Tavernari

In cancer cells, enhancer hijacking mediated by chromosomal alterations and/or increased deposition of acetylated histone H3 lysine 27 (H3K27ac) can support oncogene expression. However, how the chromatin conformation of enhancer-promoter interactions is a ...

2021

Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy

Elisa Oricchio

Loss of cell cycle controls is a hallmark of cancer and has a well-established role in aggressive B cell malignancies. However, the role of such lesions in indolent follicular lymphoma (FL) is unclear and individual lesions have been observed with low freq ...

2014

Cancer Evolution: A Multifaceted Affair

Elisa Oricchio

Cancer cells adapt and survive through the acquisition and selection of molecular modifications. This process defines cancer evolution. Building on a theoretical framework based on heritable genetic changes has provided insights into the mechanisms support ...

Amer Assoc Cancer Research2024

De novo design of protein interactions with learned surface fingerprints

Henning Paul-Julius Stahlberg, Didier Trono, Priscilla Turelli, Charlène Mireille Raymonde Raclot, Sandrine Madeleine Suzanne Georgeon, Beat Fierz, Aaron Simone Petruzzella, Anthony Marchand, Bruno Emanuel Ferreira De Sousa Correia, Elisa Oricchio, Zander Harteveld, Pablo Gainza Cirauqui, Freyr Sverrisson, Andreas Scheck, Sarah Wehrle, Stéphane Rosset, Alexandra Krina Van Hall-Beauvais, Alexandra Teslenko, Jane Marsden, Michael Bronstein, Casper Alexander Goverde, Stephen Michael Buckley, Dongchun Ni, Martin Pacesa

Physical interactions between proteins are essential for most biological processes governing life. However, the molecular determinants of such interactions have been challenging to understand, even as genomic, proteomic and structural data increase. This k ...

2023

Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies

Elisa Oricchio, Marine Jeanne Françoise Bruand

Bispecific antibodies (biAbs) used in cancer immunotherapies rely on functional autologous T cells, which are often damaged and depleted in patients with haematological malignancies and in other immunocompromised patients. The adoptive transfer of allogene ...

NATURE PORTFOLIO2024

Functional genomics lead to new therapies in follicular lymphoma

Elisa Oricchio

Recent technological advances allow analysis of genomic changes in cancer in unprecedented detail. The next challenge is to prioritize the multitude of genetic aberrations found and identify therapeutic opportunities. We recently completed a study that ill ...

2013

Whole-genome doubling drives oncogenic loss of chromatin segregation

Elisa Oricchio, Natalya Katanayeva, Ruxandra-Andreea Lambuta, Juan Diaz Miyar, Daniele Tavernari

Whole-genome doubling (WGD) is a recurrent event in human cancers and it promotes chromosomal instability and acquisition of aneuploidies(1-8). However, the three-dimensional organization of chromatin in WGD cells and its contribution to oncogenic phenotyp ...

NATURE PORTFOLIO2023

Nongenetic evolution of the tumor: from challenges to new therapeutic opportunities

Elisa Oricchio

The ability of cancer cells to change and adapt poses a critical challenge to identifying curative solutions. Tumor evolution has been extensively studied from a genetic perspective, to guide clinicians in selecting the most appropriate therapeutic option ...

WILEY2024

Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma

Julien Racle, Jessica Sordet, George Coukos, Bruno Emanuel Ferreira De Sousa Correia, Elisa Oricchio, Natalya Katanayeva, Elena Battistello, Stephanie Jocelyne Sungalee, Elie Charles Eugène Dheilly, Sarah Wehrle

Genomic alterations in cancer cells can influence the immune system to favor tumor growth. In non-Hodgkin lymphoma, physiological interactions between B cells and the germinal center microenvironment are coopted to sustain cancer cell proliferation. We fou ...

2020

Genomic studies indicate a novel combination therapy for follicular lymphoma COMMENT

Elisa Oricchio

Follicular lymphoma (FL) is an incurable form of B-cell lymphoma. Genomic alterations that inactivate RB signaling are surprisingly common in indolent FL. We show that FLs that are positive for phosphorylated RB respond to dual CDK4/BCL2 inhibition. Our re ...

TAYLOR & FRANCIS INC2021

Comparison of computational methods for the identification of topologically associating domains

Marie-Pierre Zufferey, Elisa Oricchio, Daniele Tavernari

BackgroundChromatin folding gives rise to structural elements among which are clusters of densely interacting DNA regions termed topologically associating domains (TADs). TADs have been characterized across multiple species, tissue types, and differentiati ...

2018

Antibody-peptide conjugates for targeted inhibition of cysteine proteases

Elisa Oricchio

We developed a rational approach to design peptide-based covalent inhibitors and coupled the inhibitors with antibodies for cell-specific delivery. We used this platform to generate antibody-peptide inhibitor conjugates (APICs) that target a family of prot ...

Nature Portfolio2024

Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression

Aaron Simone Petruzzella, Elisa Oricchio, Elena Battistello, Elie Charles Eugène Dheilly

Cancer evolution determines molecular and morphologic intratumor heterogeneity and challenges the design of effective treatments. In lung adenocarcinoma, disease progression and prognosis are associated with the appearance of morphologically diverse tumor ...

AMER ASSOC CANCER RESEARCH2021

De novo protein design enables the precise induction of RSV-neutralizing antibodies

Patricia Corthésy Henrioud, Sandrine Madeleine Suzanne Georgeon, Luciano Andres Abriata, Bruno Emanuel Ferreira De Sousa Correia, Elisa Oricchio, Jaume Bonet Martinez, Fabian Sesterhenn, Che Yang, Sabrina Susan Vollers, Mélanie Evelyne Villard, Elie Charles Eugène Dheilly, Stéphane Rosset

De novo protein design has been successful in expanding the natural protein repertoire. However, most de novo proteins lack biological function, presenting a major methodological challenge. In vaccinology, the induction of precise antibody responses remain ...

American Association for the Advancement of Science2020

Antibody-peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins

Luc Reymond, Florence Pojer, Albert Santamaria Martinez, Sandrine Madeleine Suzanne Georgeon, Aaron Simone Petruzzella, Bruno Emanuel Ferreira De Sousa Correia, Elisa Oricchio, Natalya Katanayeva, Sarah Wehrle, Kelvin Ka Ching Lau, Marine Jeanne Françoise Bruand

Cysteine cathepsins are a family of proteases that are relevant therapeutic targets for the treatment of different cancers and other diseases. However, no clinically approved drugs for these proteins exist, as their systemic inhibition can induce deleterio ...

Nature Portfolio2024

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

Elisa Oricchio

New anticancer drugs that target oncogenic signaling molecules have greatly improved the treatment of certain cancers. However, resistance to targeted therapeutics is a major clinical problem and the redundancy of oncogenic signaling pathways provides back ...

2011

Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma

Elisa Oricchio, Natalya Katanayeva, Maria Christine Donaldson, Elena Battistello, Stephanie Jocelyne Sungalee

Follicular lymphoma (FL) is an incurable form of B cell lymphoma. Genomic studies have cataloged common genetic lesions in FL such as translocation t(14;18), frequent losses of chromosome 6q, and mutations in epigenetic regulators such as EZH2 Using a focu ...

American Association for the Advancement of Science2017

EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains

Suliana Manley, Kyle Michael Douglass, Elisa Oricchio, Natalya Katanayeva, Maria Christine Donaldson, Elena Battistello, Timo Henry René Rey, Stephanie Jocelyne Sungalee, Daniele Tavernari

Chromatin is organized into topologically associating domains (TADs) enriched in distinct histone marks. In cancer, gain-of-function mutations in the gene encoding the enhancer of zeste homolog 2 protein (EZH2) lead to a genome-wide increase in histone-3 L ...

2019